TLR1 and infection: In our study we observed that pre-treatment with Pam3CSK4, a TLR2-TLR1 agonist, before infection induced a marked reduction of pro-inflammatory cytokines, nitrite and transaminasa levels and a decrease in the number of hepatic inflammatory foci and consequently in the mortality of infected mice.